Product NDC: | 53104-0105 |
Proprietary Name: | zidovudine |
Non Proprietary Name: | zidovudine |
Active Ingredient(s): | 50 mg/5mL & nbsp; zidovudine |
Administration Route(s): | ORAL |
Dosage Form(s): | SYRUP |
Coding System: | National Drug Codes(NDC) |
Product NDC: | 53104-0105 |
Labeler Name: | Cipla Limited |
Product Type: | HUMAN PRESCRIPTION DRUG |
FDA Application Number: | ANDA077981 |
Marketing Category: | ANDA |
Start Marketing Date: | 20080626 |
Package NDC: | 53104-0105-4 |
Package Description: | 100 mL in 1 BOTTLE (53104-0105-4) |
NDC Code | 53104-0105-4 |
Proprietary Name | zidovudine |
Package Description | 100 mL in 1 BOTTLE (53104-0105-4) |
Product NDC | 53104-0105 |
Product Type Name | HUMAN PRESCRIPTION DRUG |
Non Proprietary Name | zidovudine |
Dosage Form Name | SYRUP |
Route Name | ORAL |
Start Marketing Date | 20080626 |
Marketing Category Name | ANDA |
Labeler Name | Cipla Limited |
Substance Name | ZIDOVUDINE |
Strength Number | 50 |
Strength Unit | mg/5mL |
Pharmaceutical Classes | Human Immunodeficiency Virus Nucleoside Analog Reverse Transcriptase Inhibitor [EPC],Nucleoside Analog [Chemical/Ingredient],Nucleoside Reverse Transcriptase Inhibitors [MoA] |